GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
Carlac Filtered
The current real game changer for QED is MSC with fingers crossed all going well this could be a reality late 2024 early 2025.Should it happen what does everyone think the effect on the share price will be over 2025-26.
Alternatively should we end up with just the other 2 projects what do you think the share price will be.
A with MSC 2025?
B Just Valkor & Morocco?
Funny we all think theirs real upside but never really see many trades each day.....
Does the company need better PR?
Convb
I hope your forcast for March is correct
If the BOD concentrate mainly on getting current commercial projects live and slow down R&D. With approx. £3,000,000 in the bank and a burn rate £240,000 (which I think includes some current R&D) this should last at least 12 months at a burn of £200,000 PM 15 months at a stretch.
If Valkor happens it’s helps immensely funds jump to £4,494,500 at a burn £240,000 gives the BOD 18 months of funding ie to the end of 2024 enough time to get MSC sorted.
This funding has given the board a huge chance to get QED commercial, it’s what we have all been waiting for. They need to preserve as much money as possible over the next 12-18 months and finally sort out all these projects. If it does not happen we must surely question the viability of QED and the BOD.
So theirs the challenge as I see it. I wish the BOD all the luck in the world really hope they succeed. If they do private share holders can join me for a champagne party at my house 😊
Dustofinations spotted an additional £232,000 which is now added.
Dec 22 Cash £2,600,000
Monthly burn £240,000
Cash July 1 £1,160,000
Placing & OO £1,940,000 Gross
Total cash £3,100,000
Valkor Phase 1 £775,000
Valkor Phase 2 £387,500
Valkor Q fees £232,000
Total £1,394,500
2023 Cash + Valkor £4,494,500 should Valkor happen, otherwise it £3,100,000/need to deduct funding cost
Looks to me like their is enough cash to finally get QED commercial
Does anyone have any thoughts on the cash position I posted.
Happy to be corrected if its wrong
Bremen Welcome
II is Institutional Investors
Monthly burn rate £240,000 If you look at the filed account you will see a complete breakdown of expenses....Normal business running expensives. Salary, Rent,Travel...Plus product development et etc
Dec 22 Cash £2,600,000
Monthly burn £240,000
Cash July 1 £1,160,000
Placing & OO £1,940,000 Gross
Total cash £3,100,000
Valkor Phase 1 £775,000
Valkor Phase 2 £387,500
Total £1,162,500
2023 Cash + Valkor £4,262,500 should Valkor happen/need to deduct funding cost
Plus if we are lucky the Americias could also bring some money in within next 12 months
Looks to me like their is enough cash to finally get QED commercial
Jim89
I am far from concerned here, this is a huge opportunity...
100% agree Medium and long term looking very encouaging
Good news re below
The Board is pleased to announce that it is in advanced discussions with a large, global Tier 1 composites manufacturer with multiple sites in the US on another agreement. Further announcements will be made, as appropriate.
In the UK, demand is growing. In FY2023, growth of at least 15% is expected compared to FY2022. In FY2024, Velocity is planning for extra work from a UK manufacturer seeking to expand its capacity to meet growing demand. With expected UK growth and the start of the full rate production under the Agreement in the US, the Company can deliver profitability in FY2024.
Some good volume this morning moving the sp up
Finally we have turned the corner.....Up up and away
It will be interesting to find out which II took up the placing
Americas
QIL has recently signed a Letter of Intent with a central American power provider outlining our mutual intent for a commercial test of MSAR® and bioMSAR™ at the provider's power plant, with conclusion of a Test Agreement and site trial being the precursors for entry into a Fuel Supply Agreement. Discussions are ongoing and we expect agreements to be finalised during Q3 2023. Together with our local agents, we continue to explore other opportunities in the region. Discussions with a large refinery in the Caribbean continue to progress subject to them obtaining an operating license. Efforts continue to progress activities in Mexico with the state oil company (Pemex) and utility operators.
Morocco
In June 2022, QIL signed a new Material Transfer & Cooperation Agreement with its client in Morocco, a major chemicals Company, under which QIL will manufacture trial quantities of MSAR® and bioMSAR™ for the purpose of an industrial demonstration test at the Client's 'Site-B' facility. QIL will then provide the Client with a written report on the efficacy of using MSAR® and bioMSAR™. Provided the client-specified deliverables regarding performance and product quality are met, the parties will enter into discussions for a potential commercial supply of MSAR® and/or bioMSAR™.
In parallel with preparations for the site demonstration tests, Quadrise has since completed a technical and economic feasibility study for a potential additional industrial demonstration test at a second site of the client. This additional industrial demonstration test will be subject to future agreement, once confirmed.
Following signature of the new Agreement, volumes of MSAR® and bioMSAR™ were produced by Quadrise at a site in Europe and shipped to Morocco. Due to the process of clearing a new fuel through Moroccan customs, the commencement of the MSAR® demonstration test was subject to delays, with 60mt of MSAR® and 10mt of bioMSAR™ arriving at Site B in late February 2023. Following the completion of the site engineering set up, and finalisation of the client's production schedule, the trial commenced in May 2023.
Cold start-up of the client's combustion unit was carried out and the initial unit warm-up sequence was tested using MSAR® fuel. Whilst running at 100% a mechanical component in the pumping and heating unit failed progressively, reducing the available unit load achievable from the burner, and it became impossible to complete the testing during May as originally planned. The parties agreed to pause the trial so that the client could complete their scheduled production run, and the respective part could be replaced.
The replacement mechanical parts are now on site at the client's premises, enabling Quadrise to finalise optimisation of combustion at full load when the trial resumes.
Quadrise personnel are regularly visiting the client's site preparing for resumption of the trial in July 2023, with results expected shortly after completion of testing and joint review with the client.
Upon success, the parties will enter discussions for potential commercial supply, with a view to signing a fuel supply agreement in Q3 2023, in addition to concluding agreements for testing at other client sites as required.
MSC
The preparatory work to enable the Letter Of No Objection ("LONO") fuel trials of both bioMSAR™ and MSAR® on board the MSC Leandra continues to progress.
Following the testing of bioMSAR™ at Wärtsilä in December 2022, Quadrise and MSC are now scheduling the bioMSAR™ hazard identification and operability study as recommended by Wärtsilä, which assesses feasibility and safe operability prior to use on the vessel's 2-stroke main engine. This exercise is expected to be completed in early Q3 2023.
The MSC Leandra has recently left dry-dock, during which time it was inspected and installed with equipment designed to reduce emissions and improve vessel efficiency. The vessel, formerly the Seago Istanbul, was previously used to conduct an MSAR® trial in 2016 which, despite positive results, was halted by Maersk prior to its conclusion (due to reasons unrelated to the fuel). The emulsion fuel booster unit already on board has been inspected and will be upgraded and tested in readiness for use, so the vessel preparation required for the trial is minimal.
Quadrise is progressing discussions with potential feedstock suppliers for the trial, with the intention to conclude Tripartite Agreements with a fuel supplier and MSC as soon as possible. Following the installation and commissioning of Quadrise equipment at the supplier site, the intention is then to commence commercial-scale Proof-of-Concept and LONO trials on bioMSAR™ in H1 2024.
Once the initial MSAR® or bioMSAR™ fuel has been loaded and the on-board systems commissioned, the vessel will be bunkering bioMSAR™ throughout the Proof-of-Concept testing phase and then the LONO trial, which is currently expected to be of 4,000-hour duration.
In addition to seeking to progress this opportunity with MSC as currently envisaged, the Company continues to assess strategic means and/or partnerships which might have the possibility of accelerating the commercialisation of both bioMSAR™ and MSAR® for marine applications.
Certain of the Company's Directors and PDMRs intend to participate in the Placing or Open Offer in respect of an aggregate of up to 3,280,000 New Ordinary Shares in the Company.
Proposed Placing of New Ordinary Shares and Open Offer
Quadrise Plc (AIM:QED), the supplier of innovative energy solutions for a cleaner planet, today announces its intention to conduct a placing of up to 140 million new ordinary shares of £0.01 each in the capital of the Company ("New Ordinary Shares") (the "Placing Shares") at a price of 1.25 pence per Placing Share (the "Placing Price") to institutional and other investors to raise gross proceeds of not less than £1.0 million (the "Placing").
In addition, and in recognition of the continuing support from long-term shareholders, the Company also announces that it will be providing existing Qualifying Shareholders with the opportunity to participate in an open offer of New Ordinary Shares in the capital of the Company at the Placing Price to raise additional gross proceeds of up to a maximum of approximately £2.25 million (the "Open Offer"). The Open Offer will be launched on conclusion of the Placing and for such an amount as, together with the gross proceeds of the Placing, will see the Company raise gross proceeds of an aggregate of £3.25 million. The Placing Shares are not subject to clawback and will not be part of the Open Offer.
The total number of Placing Shares will not exceed 10 per cent. of the Company's existing ordinary share capital and no more than £1.75 million (gross) will be raised under the Placing.
The Placing will be conducted through an accelerated bookbuild (the "Bookbuild") which will be launched immediately following this Announcement. The Placing is subject to the terms and conditions set out in Appendix 1 to this Announcement.
Shore Capital Stockbrokers Limited ("Shore Capital") and VSA Capital Limited ("VSA Capital") (together, the "Bookrunners") are acting as joint bookrunners and placing agents in connection with the Placing. Cenkos Securities plc ("Cenkos") is acting as nominated adviser to the Company.
The Placing and Open Offer are conditional on, inter alia, (i) the Placing Agreement becoming unconditional in all respects in relation to the Placing and not having been terminated in accordance with its terms and (ii) Admission.
The Placing Shares and the Open Offer Shares will be issued and allotted under the Company's existing authorities obtained at the Company's last annual general meeting held on 25 November 2022.
Have I missed it? "Will be held in Q2 2023"
Due to an ongoing period of significant activity for the Company's management team, the investor conference call, usually held on the week of results, will be held in Q2 2023, when management will be able to provide a more detailed overview of activity to shareholders and interested parties. Details of this conference call will be provided in due course; shareholders with questions relating to this announcement are encouraged to send them to the Company's investor relations email address: ir@quadrise.com.